As a full-range CDMO service provider, Zencore Biologics is dedicated to providing the global biopharmaceutical clients with high quality R&D and production services during clinical development and commercialized production stages. To better meet the constantly increasing demand for production capacity both domestically and internationally, Zencore Biologics has invested and constructed a commercialized base with a building area of approximately 66,000 square meters in this blue bay of life, including two production lines for stock solution, which have been successfully put into production and can reach an extra large scale with a capacity of over 20,000 liters, used for clinical phase III and large-scale commercialized production.
This base is the first industrialization project of Zencore Biologics and an important engine for its future development as well. Therefore, when choosing a partner, Zencore Biologics attaches more importance to partners' product quality, project execution capability, GMP compliance and whether they can meet the requirements for flexible system switching. Morimatsu LifeSciences possesses strong technical strengths and extensive experiences in project delivery, based on which has earned the recognition and favor from Zencore Biologics with significant advantages in multiple aspects.
Morimatsu LifeSciences provides Zencore Biologics with an upstream and downstream production line covering a range of 5,000L, including upstream bioreactors, material replenishment systems, media preparation systems, downstream harvesting and purification systems, preparations, buffer solution preparation and storage systems, on-line dilution systems, etc., which has completed the one-stop services including process design, modular design, automatic control, manufacturing, installation, commissioning, validation, etc.
To minimize the area of the clean area and facilitate daily maintenance and operation, for the overall design of this project, Morimatsu LifeSciences has adopted a mode of black and white area separation. In addition, Morimatsu LifeSciences highly integrates the upstream and downstream production processes through the DCS automatic system, and provides the batch control formula functions that can be freely combined, which has realized the flexible construction of upstream and downstream large formula processes so as to meet the control requirements of CDMOs for the growth of cells in different species of mammals. Furthermore, Morimatsu LifeSciences provides the customized batch reporting function, which has realized paperless electronic batch reporting records. During the execution of projects, Zencore Biologics has given high credits for Morimatsu LifeSciences's excellence in professionalism, expertises, collaboration and cooperation.
They have mutually empowered each other, and have integrated closer for a brighter win-win future. Morimatsu LifeSciences has been assisting Zencore Biologics in accelerating the upgrading of industrialization and further providing efficient and high-quality full-set macromolecules CDMO technology and production services, so as to stimulate the vitality of the biopharmaceutical industry, thereby bringing more innovative therapies and medicines to patients all around the world. Both sides will take this cooperation as an opportunity and fully leverage the advantages in respective fields to create more win-win new stories in the future!
About Zencore Biologics
Zencore Biologics Co., Ltd. (hereafter referred to as “Zencore Biologics”) provides a full range of CDMO services from pre-clinical development to commercialized production, with the core businesses covering macromolecular biopharmaceuticals CDMO, antibody-drug conjugates (ADC) CDMO, catalog medium, medium customized development and production services, analysis and testing services, quality and registration services, etc. to help and boost the R&D and industrialization progress of macromolecular biopharmaceuticals in global pharmaceutical companies and scientific research institutions.
Zencore Biologics has been always upholding such values of “Hold on to the Core and Carry on the Responsibility for Ultimate Perfection”, aiming to better provide global partners with high-quality and efficient CDMO services, empower clients to rapidly transform products from concept to commercialized production, integrate best processes, and make good medicines that everyone can afford.
About Morimatsu LifeSciences
Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), mainly consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and its subsidiaries, which serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with “core equipment+value-added services+digital intelligent overall factory solutions and services” (“MVP Solutions&Services”), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular factory solutions and services.
As a diversified multinational company, Morimatsu has opened subsidiaries or advanced manufacture plants in China, Japan, Sweden, United States, India, Italy, Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by its global footprint of an efficient and professional team.
Forward-Looking Statements
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.
